Wellington Management Group LLP Lowers Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Wellington Management Group LLP trimmed its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 1.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 786,312 shares of the company’s stock after selling 11,425 shares during the quarter. Wellington Management Group LLP owned approximately 1.32% of Twist Bioscience worth $36,540,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of TWST. FMR LLC increased its holdings in shares of Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after acquiring an additional 12,327 shares during the period. BNP Paribas Financial Markets grew its stake in Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after purchasing an additional 21,357 shares during the last quarter. Verition Fund Management LLC raised its holdings in Twist Bioscience by 315.5% in the third quarter. Verition Fund Management LLC now owns 25,093 shares of the company’s stock worth $1,134,000 after purchasing an additional 19,054 shares in the last quarter. Benjamin Edwards Inc. lifted its position in shares of Twist Bioscience by 10,120.2% during the third quarter. Benjamin Edwards Inc. now owns 12,673 shares of the company’s stock valued at $572,000 after buying an additional 12,549 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in shares of Twist Bioscience by 11.8% in the 3rd quarter. Stifel Financial Corp now owns 6,967 shares of the company’s stock valued at $315,000 after buying an additional 734 shares in the last quarter.

Twist Bioscience Stock Down 3.5 %

Shares of TWST stock opened at $36.19 on Monday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The stock has a 50 day moving average of $43.80 and a 200 day moving average of $45.07. The stock has a market cap of $2.16 billion, a P/E ratio of -10.71 and a beta of 2.34.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.75) EPS. As a group, sell-side analysts expect that Twist Bioscience Co. will post -2.12 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a report on Tuesday, February 4th. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Wolfe Research began coverage on shares of Twist Bioscience in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.10.

Insider Activity

In other news, CEO Emily M. Leproust sold 1,726 shares of Twist Bioscience stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the sale, the chief executive officer now owns 660,966 shares in the company, valued at $27,549,062.88. This trade represents a 0.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,682 shares of company stock worth $1,582,011 over the last three months. 3.01% of the stock is currently owned by corporate insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.